You are here: Industry Insights > Standigm

News List

Standigm Secures $10 M From Pavilion Capital to Accelerate Its Global Competitiveness firstwordpharma
July 07, 2021
Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that they have secured a $10 million investment from Pavilion Capital, a Singapore-based investment institution.
Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership prnasia
January 11, 2021
Standigm Inc. announced that they had successfully found a new arthritis indication for an FDA-approved drug and filed a patent. This is the first successful result of their open innovation partnership, formed in July 2019.
Standigm raises $11.5M in Series B Round biospectrumasia
April 02, 2019
Standigm will use the funds to scale the AI technology platforms and advance its drug discovery pipelines toward license-out
Standigm, an AI based Drug Discovery Company, Launched AI Drug Discovery Services Publicly at Bio-Eu prnasia
November 14, 2017
CEO and cofounder of Standigm, Jinhan Kim, is introducing the new AI based drug discovery services, ‘Expander’ and ‘Hunter’ at the Bio-Europe 2017 in Berlin, Germany. Photo credit: Standigm